Advertisement
News
Advertisement

Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay - Harmony Prenatal TestT - and Publication of Study on Specimen Transport

Mon, 02/06/2012 - 7:09am
The Associated Press

/FROM PR NEWSWIRE DALLAS 888-776-3971/

STK

IN MEQ MTC HEA PUB

SU PDT SVY WOM

-- WITH PHOTO -- TO BUSINESS, HEALTH, AND MEDICAL EDITORS:

Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay -

Harmony Prenatal TestT - and Publication of Study on Specimen

Transport

SAN JOSE, Calif., Feb. 6, 2012 /PRNewswire/ -- Aria Diagnostics, a

molecular diagnostics company, today announced that its new prenatal

test has been named the Harmony Prenatal TestT. The test is a directed

non-invasive approach to cell-free DNA (cfDNA) analysis in maternal

blood to detect common trisomies linked to genetic disorders.

(Logo: http://photos.prnewswire.com/prnh/20120109/NY31734LOGO )

"The name perfectly describes Aria's goal of bringing harmony to

patients, medical service providers and healthcare networks by

offering an advanced prenatal test that is highly accurate, accessible

and affordable to a broad population," said Todd Whitson, vice

president of sales and commercial operations at Aria Diagnostics. "The

current landscape of prenatal testing can be cumbersome and confusing.

We hope to streamline the process by providing this simple blood

test."

The Harmony Prenatal Test utilizes new technology which couples

innovative biochemistry, DANSRT, and a proprietary algorithm, FORTET,

to efficiently analyze patients' blood samples.

The company also announces the publication of a study on the effects

of temperature during shipping of blood specimens. The article titled,

"Influence of Temperature during Transportation on Cell-Free DNA

Analysis" is published online in the journal Fetal Diagnosis and

Therapy and available at

http://content.karger.com/produktedb/produkte.asp?DOI000335020. This

publication follows several recent data announcements, including the

peer-reviewed journal publication of three clinical studies in more

than 1,000 patients and the launch of a large scale clinical trial

comparing the Harmony Prenatal Test with the standard first-trimester

screening test in 25,000 women.

The company will be exhibiting information about the Harmony Prenatal

Test and its proprietary technology approach at the Society for

Maternal Fetal Medicine's 32nd Annual Meeting in Dallas, TX, Feb.

8-11.

About Aria Diagnostics

Aria Diagnostics, Inc., is a molecular diagnostics company committed

to providing safe, highly accurate and affordable prenatal tests for

maternal and fetal health. Led by an experienced team, Aria is using

its proprietary technology to perform a directed analysis of cell-free

DNA in blood. Aria's simple blood test equips pregnant women and their

healthcare providers with reliable information to make decisions

regarding their health, without creating unnecessary stress or

anxiety.

The company began operations in 2010 and is headquartered in San Jose,

Calif. For more information, visit www.ariadx.com.

SOURCE Aria Diagnostics, Inc.

-0- 02/06/2012

/CONTACT: Traci Tournoux, HealthStar PR, +1-646-722-8830, ttournoux@healthstarpr.com

/Photo: http://photos.prnewswire.com/prnh/20120109/NY31734LOGO

PRN Photo Desk, photodesk@prnewswire.com

/Web Site: http://www.ariadx.com

CO: Aria Diagnostics, Inc.; Society for Maternal Fetal Medicine's 32nd Annual Meeting

ST: California Texas

IN: MEQ MTC HEA PUB

SU: PDT SVY WOM

PRN

-- NY47953 --

0000 02/06/2012 14:00:00 EDT http://www.prnewswire.com

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading